Combination therapies using targeted anti-cancer agents have the potential to overcome resistance, enhance responses and reduce toxicity. Jaaks et al. screen the Genomics of Drug Sensitivity in Cancer (GDSC) database to measure the effects of 2,025 pairwise drug combinations in 125 breast, colorectal and pancreatic cancer cell lines.
